Meeting
2014 ASCO Annual Meeting
Oncolytic viral therapy for malignant gliomas using myxoma virus deleted for antiapoptotic M11L gene.
Authors
Peter A. J. Forsyth
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Peter A. J. Forsyth , Brienne McKenzie , Alexandra Pisklakova , Rajappa Kenchappa , Grant McFadden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Viral Therapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3105)
DOI
10.1200/jco.2014.32.15_suppl.3105
Abstract #
3105
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2011 ASCO Annual Meeting
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
First Author: O. L. Chinot
Poster
2023 ASCO Annual Meeting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
First Author: Dinu Stefan
Poster
2020 ASCO Virtual Scientific Program
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
First Author: Erica Hlavin Bell